All In Biotech

Drug Trial Radar · NCT07182682

A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Anti-Tumor Efficacy and Safety of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery (WU-KONG16)

Last checked: Nov 20, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Dec 1, 2025

Primary completion

Sep 2029

Study completion Jan 2031

Sponsor

Sponsor type
Industry
First posted
Sep 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the efficacy and safety of sunvozertinib versus placebo as adjuvant therapy in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins) or P-loop and αC-helix compression (PACC) mutations, who have had radical surgery, regardless of adjuvant chemotherapy.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • sunvozertinibDrug

    Participants will receive oral administration of sunvozertinib 200 mg QD following randomization, with each treatment cycle defined as 21 days, until meeting any treatment discontinuation criteria (i.e, objective disease recurrence, intolerable adverse event \[AE\], completion of 3-year \[156-week\] treatment period, study termination, death, treatment or study withdrawal by participants, whichever occurs first).

  • Matching PlaceboDrug

    Participants will receive oral administration of placebo 200 mg QD following randomization, with each treatment cycle defined as 21 days, until meeting any treatment discontinuation criteria (i.e, objective disease recurrence, intolerable adverse event \[AE\], completion of 3-year \[156-week\] treatment period, study termination, death, treatment or study withdrawal by participants, whichever occurs first).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free survival (DFS) by investigator assessmentTime frame: Up to approximately 5 years after the first participant is randomized

Locations

49 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, China · Not yet recruiting

  • Beijing Chest Hospital, Capital medical university

    Beijing, China · Not yet recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, China · Not yet recruiting

  • China-Japan Friendship hospital

    Beijing, China · Not yet recruiting

  • Peking Union Medical College Hospital

    Beijing, China · Not yet recruiting

  • Xuanwu Hospital Capital Medical University

    Beijing, China · Not yet recruiting

  • The First Hospital of Jilin University

    Changchun, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, China · Not yet recruiting

  • The Third Xiangya Hospital of Central South University

    Changsha, China · Not yet recruiting

  • Xiangya Hospital of Central South University

    Changsha, China · Not yet recruiting

  • Sichuan Cancer Hospital

    Chengdu, China · Not yet recruiting

  • West China Hospital Sichuan University

    Chengdu, China · Not yet recruiting

  • Fujian Cancer Hospital

    Fuzhou, China · Not yet recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, China · Not yet recruiting

  • Affiliated Cancer Hospital and Institute of Guangzhou Medical University

    Guangzhou, China · Not yet recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, China · Not yet recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, China · Not yet recruiting

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, China · Not yet recruiting

  • The First Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, China · Not yet recruiting

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, China · Not yet recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, China · Not yet recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, China · Not yet recruiting

  • Anhui Provincial Cancer Hospital

    Hefei, China · Recruiting

  • Jinan Central Hospital

    Jinan, China · Not yet recruiting

  • Shandong Cancer Hospital

    Jinan, China · Recruiting

  • Yunnan Cancer Hospital

    Kunming, China · Not yet recruiting

  • Jiangxi Provincial People 's Hospital

    Nanchang, China · Not yet recruiting

  • Jiangsu Province Hospital

    Nanjing, China · Not yet recruiting

  • Nanjing Chest Hospital

    Nanjing, China · Not yet recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, China · Not yet recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, China · Not yet recruiting

  • Shanghai Chest Hospital

    Shanghai, China · Not yet recruiting

  • Shanghai East Hospital

    Shanghai, China · Not yet recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, China · Recruiting

  • Zhongshan Hospital Fudan University

    Shanghai, China · Not yet recruiting

  • Liaoning Cancer Hospital & Institute

    Shenyang, China · Not yet recruiting

  • The First Hospital of China Medical University

    Shenyang, China · Not yet recruiting

  • Shanxi Cancer hospital (Shanxi Cancer institute)

    Taiyuan, China · Not yet recruiting

  • Shanxi Provincial people's hospital

    Taiyuan, China · Not yet recruiting

  • Taizhou Hospital, Zhejiang Province

    Taizhou, China · Not yet recruiting

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.